Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD) (IVF008)

This study has been completed.
Information provided by (Responsible Party):
Natera, Inc. Identifier:
First received: November 30, 2009
Last updated: April 1, 2014
Last verified: April 2014
Gene Security Network has developed a novel technology called Parental SupportTM (PS) which is used for Preimplantation Genetic Screening/Diagnosis (PGS/D) during in vitro fertilization (IVF). This technology allows IVF physicians to identify embryos, prior to transfer to the uterus, which have the best chance of developing into healthy children. The purpose of this study is to validate clinical use of PS to detect specific genetic mutation(s) known to cause severe inheritable diseases in embryos produced by at-risk couples. This may be done while simultaneously testing these embryos for aneuploidy. This study will allow for first of its kind commercial PGS/D testing to detect disease-associated genetic mutations together with aneuploidy screening.

Condition Intervention
Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs)
Other: preimplantation diagnosis

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: First Use of Parental Support Technology(R) for Single Gene Analysis Plus Aneuploidy Screening in Preimplantation Genetic Diagnosis

Resource links provided by NLM:

Further study details as provided by Natera, Inc.:

Primary Outcome Measures:
  • Confirm diagnosis through prenatal diagnosis (CVS or amniocentesis) [ Time Frame: 10-20 weeks post intervention ]

Enrollment: 56
Study Start Date: November 2009
Study Completion Date: March 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PGD testing Other: preimplantation diagnosis
genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
Other Name: Parental Support Technology


Ages Eligible for Study:   up to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • couple (mother and father)at risk to have a child with a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
  • Able to provide laboratory report from commercial CLIA certified laboratory confirming presence of disease associated mutation in mother and/or father
  • couple planning to go through IVF and desiring PGD for the specified mutation
  • Father (male) willing and able to provide sperm sample
  • Maternal (female's) age <40 years (e.g., 39 or younger)
  • CVS/Amnio planned once the pregnancy occurs; willing/able to provide amnio/cvs sample for confirmatory testing or provide test results of confirmatory testing performed by an external CLIA certified laboratory.
  • FSH <10 (FSH = Follicle Stimulating Hormone. FSH is an indicator of egg quality and rough predictor of egg stimulation success. FSH is routinely measured by the IVF center prior to beginning an IVF cycle.)

Exclusion Criteria:

  • Couples without prior documentation of genetic mutation as specified above
  • Adult couples where the male partner is not willing, able, or available to provide a semen sample.
  • Maternal age >=40 years
  • Couple unwilling to have amnio/cvs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01023048

United States, California
Gene Security Network
Redwood City, California, United States, 94063
Sponsors and Collaborators
Natera, Inc.
Principal Investigator: Matthew Rabinowitz, PhD Natera, Inc.
  More Information

Responsible Party: Natera, Inc. Identifier: NCT01023048     History of Changes
Other Study ID Numbers: IVF008
Study First Received: November 30, 2009
Last Updated: April 1, 2014

Keywords provided by Natera, Inc.:
preimplantation diagnosis

Additional relevant MeSH terms:
Cystic Fibrosis
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Chromosome Aberrations
Pathologic Processes processed this record on April 28, 2017